2026 Fiscal Year Reimbursement Increase Seen as Opportunity for “Improving Quality of Care” – Japan Association of Chronic Care Medicine Chairman Hashimoto

News Highlights

This report covers statements by Chairman Hashimoto of the Japan Association of Chronic Care Medicine (JACM), who believes the 2026 fiscal year reimbursement revision, expected to be a positive adjustment, should be viewed as an investment opportunity for “improving the quality of care.” The revision is seen as a catalyst for initiatives aimed at enhancing quality. From the perspective of medical M&A and business succession, key discussion points include management and succession strategies that consider the revision cycle, the economies of scale through group formation, and the utilization of tax schemes such as transitioning to specific medical corporations or social medical corporations.

M&A Medical Editorial Department’s Perspective

The prospect of a positive reimbursement revision in fiscal year 2026 is welcome news for healthcare facility managers. However, as Chairman Hashimoto of JACM points out, it is crucial to go beyond mere revenue increases and strongly focus on investing in “improving the quality of care.” This has extremely important implications for considering M&A and business succession. Substantial funds are required for facility investments and human resource development to enhance quality, and many medical institutions find it difficult to manage this independently. In such circumstances, strengthening the management base through group formation or enjoying tax benefits by transitioning to specific medical corporations or social medical corporations can be viable options for securing investment funds for quality improvement while achieving sustainable business operations. This strategic approach is particularly urgent for small and medium-sized medical institutions that play a vital role in regional healthcare.

Key Discussion Points from This News

• Management decisions are needed to view the positive reimbursement revision as a source of funds for quality improvement investments.
• Securing funds for facility investments and human resource development necessary for quality improvement may pose a challenge for independent operations.
• Economies of scale through group formation can contribute to maintaining facility standards and reducing the burden of facility investment.
• Transitioning to specific medical corporations or social medical corporations can support quality improvement investments through tax benefits.

Practical Questions Arising from This News

• In what specific quality improvement measures should the positive reimbursement revision be invested for the most effective results?
• What kind of operational efficiencies can be expected from group formation compared to independent management?
• What procedures and conditions are necessary for transitioning to a specific medical corporation or social medical corporation?

If You Feel “Should I Consult Too?”

You are planning to allocate the positive adjustment from the 2026 fiscal year reimbursement revision to future quality improvement investments but are concerned about independent facility investments and securing human resources. You also want to understand the specific benefits of group formation or changes in corporate status with an eye on future business succession. You should consider consulting if you wish to receive expert advice on the optimal options for your institution’s situation.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a completely success-fee basis as a certified M&A support institution by the Small and Medium Enterprise Agency. We handle consultations with strict confidentiality. Free consultation here